| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Correction: Incorrect inclusion of MAR text in earlier release.Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| Do | Klaria Pharma Holding AB: Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 204 | GlobeNewswire (Europe) | Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting... ► Artikel lesen | |
| 02.03. | Klaria Pharma Holding AB (publ) Summons to Extraordinary General Meeting | 2 | Cision News | ||
| 20.02. | Klaria Pharma Holding AB: Klaria Year-End Report | 561 | GlobeNewswire (Europe) | Klaria Year-End Report Q4 2025
1 January-31 December 2025
SummaryFourth quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for... ► Artikel lesen | |
| 23.12.25 | Klaria Pharma Holding AB: Klaria accelerates its business development work in collaboration with BDO | 723 | GlobeNewswire (Europe) | With Klaria's product, Sumatriptan Alginate Film, approved in the EU and set to launch in 2026 in the largest EU markets, the company has now engaged BDO LLP's UK Life Sciences & Healthcare M&A team... ► Artikel lesen | |
| 17.12.25 | Klaria Pharma Holding AB: Klaria Receives Positive Opinion on Sumatriptan Oral Film Patent Application | 161 | GlobeNewswire (Europe) | Klaria announced earlier in the year that it had submitted an additional patent application on the sumatriptan oral film product to further protect the product and potentially extend its market exclusivity.... ► Artikel lesen | |
| 26.11.25 | Klaria Pharma Holding AB Q3 Sales Decline | - | RTTNews | ||
| 26.11.25 | Klaria Pharma Holding AB: Klaria Interim Report Q3 2025 | 179 | GlobeNewswire (Europe) | Klaria Interim Report
1 July - 30 September 2025
Summary of the interim reportThird quarter of 2025
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 28.08.25 | Klaria Pharma Holding AB: Klaria Interim Report Q2 2025 | 291 | GlobeNewswire (Europe) | Klaria interim report
1 April-30 June 2025
Summary of the interim reportSecond quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses... ► Artikel lesen | |
| 18.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.06.2025 | 720 | Xetra Newsboard | Das Instrument FCC ES0122060314 FOMENT.CON.CONTR.INH.EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 18.06.2025 The instrument FCC ES0122060314 FOMENT.CON.CONTR.INH.EO 1 EQUITY is traded ex capital... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 49,750 | +0,35 % | EQS-News: Evotec SE: Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer klinischen Studie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer... ► Artikel lesen | |
| DERMAPHARM | 40,900 | -0,73 % | Ihre wichtigsten Termine: Nvidia, Qualcomm, Audi, Dermapharm, Docusign und Fraport stehen heute im Fokus! | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland: Fraport... ► Artikel lesen | |
| SYNBIOTIC | 2,045 | +3,91 % | EQS-News: SYNBIOTIC SE: Globale Dynamik im Cannabismarkt: Neue Signale aus den USA stärken langfristige Perspektiven für Europa und SYNBIOTIC | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Marktbericht/Sonstiges
Globale Dynamik im Cannabismarkt: Neue Signale aus den USA stärken langfristige Perspektiven für Europa und SYNBIOTIC... ► Artikel lesen | |
| INCYTE | 78,30 | -0,33 % | Incyte-Aktie: Was ist 2026 zu erwarten? | Seit unseres ersten Tipps im Juli vergangenen Jahres konnte sich die Aktie von Incyte zunächst sehr stark entwickeln und verzeichnete wenige Monate später mehr als +50% Kursgewinn. Seit einigen Wochen... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 5,350 | +0,28 % | Green Thumb Industries Reports Fourth Quarter and Full Year 2025 Results | CHICAGO and VANCOUVER, British Columbia, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,960 | -4,95 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness Announces the Grand Opening of Its Newest Location in Ottawa, Ontario | Toronto, Ontario--(Newsfile Corp. - March 20, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| CSPC PHARMA | 0,980 | +2,00 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE LONG-ACTING INJECTION (SYH2082 INJECTION) OBTAINS CLINICAL ... | ||
| TONIX PHARMACEUTICALS | 13,700 | +5,38 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 | ||
| KHIRON LIFE SCIENCES | 0,029 | -100,00 % | Khiron Life Sciences Corp: Khiron Life Sciences warrants to expire Nov. 26 | ||
| PSYCHED WELLNESS | 0,005 | 0,00 % | Psyched Wellness Ltd.: Psyched Wellness Announces Closing of Private Placement and Shares for Debt Transaction and Resignation of a Director | Toronto, Ontario--(Newsfile Corp. - March 20, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,260 | +0,71 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| OPKO HEALTH | 0,999 | +0,95 % | OPKO Health beruft Subbarao V. Uppaluri in den Verwaltungsrat | ||
| COSMO PHARMACEUTICALS | 83,00 | 0,00 % | Cosmo Pharmaceuticals N.V.: Cosmo Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026 | Dublin, Ireland--(Newsfile Corp. - March 16, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced its participation at NVIDIA GTC 2026, the world's leading conference... ► Artikel lesen | |
| SWEET EARTH | 0,324 | -100,00 % | Sweet Earth Holdings Corp (4): Sweet Earth amends merger agreement with Vesalius | ||
| LEEF BRANDS | 0,177 | +9,94 % | LEEF Brands Inc.: LEEF Brands Announces Full Early Conversion of CAD Convertible Debentures | VANCOUVER, British Columbia, Dec. 29, 2025 (GLOBE NEWSWIRE) -- LEEF Brands, Inc. (CSE: LEEF, OTCQB: LEEEF) ("LEEF" or the "Company"), a leading multi-state operator, today announced the full early... ► Artikel lesen |